Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant operational synergies are anticipated in procurement, R&D logistics and production.
Read the full article: Biosynex Completes Acquisition of Chembio Diagnostics, Inc. //
Source: https://www.globenewswire.com/news-release/2023/04/27/2656944/21088/en/Biosynex-Completes-Acquisition-of-Chembio-Diagnostics-Inc.html